U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H21N3.ClH
Molecular Weight 255.787
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUINPIROLE HYDROCHLORIDE

SMILES

Cl.[H][C@]12CCCN(CCC)[C@]1([H])CC3=C(C2)NN=C3

InChI

InChIKey=HJHVRVJTYPKTHX-HTMVYDOJSA-N
InChI=1S/C13H21N3.ClH/c1-2-5-16-6-3-4-10-7-12-11(8-13(10)16)9-14-15-12;/h9-10,13H,2-8H2,1H3,(H,14,15);1H/t10-,13-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C13H21N3
Molecular Weight 219.3259
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9806217 | https://www.ncbi.nlm.nih.gov/pubmed/2566488 | https://www.ncbi.nlm.nih.gov/pubmed/9926830 | https://www.ncbi.nlm.nih.gov/pubmed/28434589

Quinpirole (LY 171,555) is a psychoactive drug and research chemical which acts as a selective D2 and D3 receptor agonist. Quinpirole is the most widely used D2 agonist in in vivo and in vitro studies. Specific quinpirole binding in rat brain was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. Saturation analysis revealed high affinity binding characteristics (KD = 2.3 nM) which were confirmed by association-dissociation kinetics. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles. A variety of drugs, most notably monoamine oxidase inhibitors (MAOls), inhibit the binding of [3H]quinpirole, but not [3H]spiperone or [3H](-)N-n-Propylnorapomorphine, in rat striatal membranes by a mechanism that does not appear to involve the enzymatic activity of MAO. Clinically antidepressant MAOIs exhibited selectivity between sites labeled by [3H]quinpirole and [3H]spiperone as did a number of structurally related propargylamines and N-acylethylenediamine derivatives and other drugs such as debrisoquin and phenylbiguanide. Quinpirole has been shown to increase locomotion and sniffing behavior in mice and induces compulsive behavior symptomatic of obsessive compulsive disorder in rats.

Originator

Sources: Brain research (1981), 225, (2), 347-56.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.8 nM [EC50]
19.0 nM [EC50]
9.9 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist.
1984 Sep
A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice.
1990 Nov
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
1990 Sep 13
Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.
1991
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.
1991 Apr 18
Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists.
1991 Oct
Strain differences in clonidine-induced aggressiveness in mice and its interaction with the dopamine system.
1993 Apr
Effects of dopamine D1 and D2 receptor agonists and antagonists on seizures induced by chemoconvulsants in mice.
1993 Apr-May
Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
1993 Aug 15
Depression of high-threshold calcium currents by activation of human D2 (short) dopamine receptors expressed in differentiated NG108-15 cells.
1994 Apr
Reserpine increases Fos activity in the rat basal ganglia via a quinpirole-sensitive mechanism.
1994 May
Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression.
1994 Sep 26
K-channel blockers attenuate the presynaptic effects of the D2/D3 agonist quinpirole in monkeys.
1995 Aug
Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
1995 Feb
A functional test identifies dopamine agonists selective for D3 versus D2 receptors.
1995 Jan 26
Lack of discrimination by agonists for D2 and D3 dopamine receptors.
1995 Jul
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
1995 Jun 23
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
1995 Nov
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
1995 Nov
Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway.
1995 Oct
Roxindole, a potential antidepressant. I. Effect on the dopamine system.
1996
Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
1996 Dec
Cerebrocortical Fos expression following dopaminergic stimulation: D1/D2 synergism and its breakdown.
1996 Jul 22
Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors.
1996 Mar 1
Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity.
1996 Nov 21
Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway.
1997 Apr 25
Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
1997 Jan
Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
1997 Jan-Feb
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
1997 Nov
Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat.
1997 Oct 8
Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.
1998
Potentiation of D2-dopamine receptor-mediated suppression of zif 268 by non-competitive NMDA receptor antagonists in reserpinized rats.
1998 Aug 15
Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions.
1998 May
Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations.
1998 May 1
Acute nicotine pretreatment augments dopaminergic pulmonary vasodilation.
1998 Oct
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
2005 Feb 23
Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys.
2005 Jun-Jul
Locomotor activity and cocaine-seeking behavior during acquisition and reinstatement of operant self-administration behavior in rats.
2005 May 28
The influence of central administration of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice.
2006 Jan
Delayed L-DOPA-induced hyperalgesia.
2006 Nov
Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
2006 Oct 13
Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress.
2007 Jan
Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants.
2007 Jun 27
Maternal lead exposure produces long-term enhancement of dopaminergic reactivity in rat offspring.
2007 Oct
Effects of (-)-epigallocatechin gallate on the development of morphine-induced physical dependence.
2007 Sep
Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
2009 Jul
Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats.
2009 Sep-Oct
Amphetamine up-regulates activator of G-protein signaling 1 mRNA and protein levels in rat frontal cortex: the role of dopamine and glucocorticoid receptors.
2010 Jun 16
Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.
2010 Sep 1
The role of the dopamine transporter in dopamine-induced DNA damage.
2011 May
Patents

Patents

Sample Use Guides

0.5 mg/kg (two injections/week)
Route of Administration: Other
In Vitro Use Guide
Adult, male, Sprague-Dawley rats (200-250g; Harlan Labs, Indianapolis, IN) were sacrificed by decapitation, the brains rapidly removed and dissected on ice. Striatal tissue was homogenized in 30 vol. ice-cold 0.32 M sucrose using a glass homogenizer and Teflon pestle. The crude nuclear fraction (P1), the pellet formed from centrifugation of the pellet at 1,000 x g for 10 mitt; the crude synaptosomal fraction (P2), the pellet formed by the centrifugation of the resulting supernatant at 20,000 x g for 30 min; Subfractionation of the crude synaptosomal fraction (P2) was performed by centrifugation of freshly prepared P2 fraction suspended in 0.32 M sucrose over a discontinuous gradient of 0.8 M and 1.2 M sucrose at 110,000 x g for 70 min. Three subfractions were collected. The myelin fraction (P2A) was collected at the 0.32 M/O.8 M sucrose interface; the synaptosomal fraction (P2B) at the 0.8 /1.2 M sucrose interface; and the mitochondrial fraction (P2C), the final pellet. All resulting fractions were resuspended in assay buffer and centrifuged at 100,000 x g for 30 min. The resulting pellets were used for receptor binding assays. The final fraction pellets were resuspended in assay buffer (50 mM Tris-HCl, 5 mM KCI, 2 mM MgCl2, and 2 mM CaCl2, pH 7.4 at 23°C) to yield a final protein concentration of 400 mkg/tube. Binding assays were performed in duplicate in disposable polystyrene tubes. Saturation analyses were performed in the major subcellular fractions to determine radioligand affinity. For saturation analyses, eight concentrations of [3H]quinpirole (43 Ci/mmol; NEN DuPont Research Products, Boston, MA) were used (0.1 to 30 nM). Because [3H]quinpirole exhibited similar affinity in the major subcellular fractions, single point analyses were used for subsequent experiments. For single point studies, the final concentration of [3H]quinpirole was ~2 nM Binding was initiated by the addition of resuspended subcellular fractionate. The total assay volume was 0.5 ml. Tubes were incubated at 23°C for 4 h
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:23:57 GMT 2023
Edited
by admin
on Fri Dec 15 15:23:57 GMT 2023
Record UNII
T6I2W5V2K1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUINPIROLE HYDROCHLORIDE
USAN  
USAN  
Official Name English
QUINPIROLE HYDROCHLORIDE [USAN]
Common Name English
(-)-(4AR,8AR)-4,4A,5,6,7,8,8A,9-OCTAHYDRO-5-PROPYL-1H-PYRAZOLO(3,4-G)QUINOLINE MONOHYDROCHLORIDE
Common Name English
LY171555
Code English
QUINPIROLE HCL
Common Name English
LY-171555
Code English
1H-PYRAZOLO(3,4-G)QUINOLINE, 4,4A,5,6,7,8,8A,9-OCTAHYDRO-5-PROPYL-, MONOHYDROCHLORIDE, (4AR-TRANS)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL240773
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
PRIMARY
NCI_THESAURUS
C152129
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
PRIMARY
CAS
85798-08-9
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
PRIMARY
FDA UNII
T6I2W5V2K1
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID8045519
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
PRIMARY
PUBCHEM
55397
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
PRIMARY
USAN
U-9
Created by admin on Fri Dec 15 15:23:57 GMT 2023 , Edited by admin on Fri Dec 15 15:23:57 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY